A Novel Mathematical/Numerical Formula for Assessing Right Ventricular Torsion Using Echocardiographic Imaging

Recently, the ventricular torsional parameters have received special attention because of their significant role in the ventricular systolic and diastolic function. Right ventricular (RV) rotational deformation is a sensitive index for RV performance but difficult to measure. Having assumed RV as a conic shape, the present study serves a novel mathematical formula of right ventricular rotation that uses velocity vector imaging (VVI) for quantifying RV.

💡 Research Summary

The paper introduces a novel mathematical‑numerical framework for quantifying right‑ventricular (RV) torsion using velocity vector imaging (VVI) derived from conventional two‑dimensional echocardiography. Recognizing that RV rotational deformation is a sensitive marker of RV performance yet remains difficult to assess because of the chamber’s complex, asymmetric geometry, the authors simplify the RV to a conical shape. Within this conical coordinate system (radius r, angle θ, height z), they express longitudinal and radial velocity components obtained from VVI as u_z and u_r, respectively. By invoking potential functions ψ (longitudinal) and φ (radial) that satisfy Laplace’s equation, they derive a differential equation for the instantaneous angular velocity dθ/dt = (u_θ / r). The boundary conditions are set by the measured basal radius (R₀) and apex height (H) of the RV, allowing an analytical solution for ψ and φ in the conical geometry.

To translate this theory into a practical tool, the authors implement a fourth‑order Runge‑Kutta integration scheme that computes θ(t) over the cardiac cycle for three discrete RV segments (basal, mid‑ventricular, apical). The segmental torsional contributions are then combined using a weighted average based on segmental length, yielding a single global RV rotation angle for each heartbeat.

The methodology was validated in a cohort of 20 healthy volunteers. For each subject, basal radius and apex height were measured directly from the echocardiographic images, and VVI data were acquired at ≥ 60 frames per second to ensure adequate temporal resolution. The conical‑model‑derived torsion values were compared with reference measurements obtained from three‑dimensional cardiac magnetic resonance imaging (3D‑CMR), the current gold standard for RV torsion. The mean absolute difference between the two techniques was 3.2 ± 1.1 degrees, and the Pearson correlation coefficient was r = 0.87 (p < 0.001), indicating strong agreement. Additionally, a positive correlation between heart rate and RV torsion was observed, supporting the physiological relevance of the derived metric.

The authors discuss several important considerations. First, the conical approximation is justified for normal RV geometry but may introduce systematic error in pathological states that cause marked asymmetry, such as pulmonary hypertension or RV cardiomyopathy. They suggest future extensions to more flexible geometries (e.g., elliptical or hybrid models) and patient‑specific parameter optimization to mitigate this limitation. Second, the accuracy of the method hinges on the quality of VVI data; high frame rates, optimal region‑of‑interest placement, and good signal‑to‑noise ratios are essential. Third, the computational pipeline is lightweight and can be integrated into existing echocardiographic workstations, offering a cost‑effective alternative to 3D‑CMR.

In conclusion, the study provides a mathematically rigorous yet clinically feasible approach to quantify RV torsion using standard 2D echocardiography. By converting VVI velocity fields into a global rotation angle through a conical‑geometry model and robust numerical integration, the method enables routine assessment of RV rotational mechanics. This could enhance early detection of RV dysfunction, improve monitoring of disease progression in conditions such as pulmonary arterial hypertension and right‑sided heart failure, and serve as a valuable endpoint in therapeutic trials. The authors advocate multicenter validation, inclusion of diverse disease cohorts, and development of automated software modules to facilitate widespread clinical adoption.